Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$68.68 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
327.07 million
Earnings per share
-0.014
Dividend per share
N/A
Year To Date Return
81.48%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Healthcare Shares
2 ASX healthcare shares racing higher on positive updates
Healthcare Shares
ASX All ords biotech stock explodes 120% on regulatory green light
Share Market News
Guess which ASX All Ords share just crashed 52% on a TGA update
Share Gainers
It's not all bad news for ASX All Ords shares today. Here are some big winners
Healthcare Shares
2 ASX healthcare shares smashing the All Ords today
Healthcare Shares
The chair of this ASX All Ords company just sold $6.5 million of shares. What gives?
Healthcare Shares
Rhythm Biosciences share price lifts 5% on TGA news
Healthcare Shares
Here's why the Rhythm Biosciences (ASX:RHY) share price soared 8% today
Healthcare Shares
Here's why the Rhythm (ASX:RHY) share price is up 11% today
Healthcare Shares
Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets
Healthcare Shares
Rhythm Biosciences (ASX: RHY) share price slumps amid 'pivotal' board changes
Share Gainers
Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Feb 2026 | $0.21 | $0.01 | 4.88% | 1,451,816 | $0.23 | $0.24 | $0.21 |
| 16 Feb 2026 | $0.21 | $-0.01 | -4.76% | 600,062 | $0.21 | $0.22 | $0.21 |
| 13 Feb 2026 | $0.21 | $-0.03 | -12.50% | 1,375,589 | $0.24 | $0.24 | $0.21 |
| 12 Feb 2026 | $0.24 | $-0.01 | -4.08% | 574,887 | $0.25 | $0.25 | $0.23 |
| 11 Feb 2026 | $0.25 | $0.02 | 8.89% | 1,452,574 | $0.26 | $0.27 | $0.25 |
| 10 Feb 2026 | $0.23 | $-0.03 | -11.76% | 2,361,966 | $0.25 | $0.26 | $0.21 |
| 09 Feb 2026 | $0.26 | $0.01 | 4.08% | 2,469,619 | $0.26 | $0.27 | $0.24 |
| 06 Feb 2026 | $0.25 | $0.01 | 4.26% | 3,593,802 | $0.23 | $0.28 | $0.21 |
| 05 Feb 2026 | $0.24 | $0.06 | 34.29% | 4,473,786 | $0.18 | $0.24 | $0.18 |
| 04 Feb 2026 | $0.18 | $-0.02 | -10.53% | 371,205 | $0.19 | $0.19 | $0.18 |
| 03 Feb 2026 | $0.19 | $0.04 | 26.67% | 2,755,061 | $0.17 | $0.20 | $0.17 |
| 02 Feb 2026 | $0.15 | $0.01 | 6.90% | 438,104 | $0.15 | $0.17 | $0.15 |
| 30 Jan 2026 | $0.15 | $-0.03 | -17.65% | 1,546,739 | $0.17 | $0.17 | $0.14 |
| 29 Jan 2026 | $0.17 | $0.02 | 13.33% | 2,553,566 | $0.15 | $0.18 | $0.15 |
| 28 Jan 2026 | $0.15 | $0.01 | 7.14% | 644,130 | $0.15 | $0.16 | $0.15 |
| 27 Jan 2026 | $0.14 | $-0.01 | -6.67% | 217,846 | $0.16 | $0.16 | $0.14 |
| 23 Jan 2026 | $0.15 | $-0.01 | -6.25% | 860,905 | $0.17 | $0.17 | $0.15 |
| 22 Jan 2026 | $0.16 | $0.00 | 0.00% | 869,477 | $0.17 | $0.17 | $0.16 |
| 21 Jan 2026 | $0.16 | $0.01 | 6.67% | 730,170 | $0.15 | $0.16 | $0.15 |
| 20 Jan 2026 | $0.15 | $0.00 | 0.00% | 128,926 | $0.15 | $0.16 | $0.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Dec 2025 | David Atkins | Issued | 100,000 | $8,600 |
Issue of options.
|
| 02 Dec 2025 | Gavin Fox-Smith | Issued | 277,777 | $23,888 |
Issue of options.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 750,000 | $66,000 |
Issue of options.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 1,027,777 | $99,999 |
Issue of securities.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $39,600 |
Issue of options.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $45,000 |
Issue of securities.
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
| 01 Dec 2025 | David Atkins | Issued | 1,093,001 | $108,300 |
Issue of securities.
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
| 01 Dec 2025 | David Atkins | Issued | 466,820 | $41,080 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Atkins | Chief Executive OfficerManaging Director | May 2024 |
Dr Atkins is a healthcare leader with global markets experience across a board range of life sciences and healthcare disciplines, having gained experience in R&D, product development and commercialization across biotech, medical device, IVD and data-driven solutions in all global markets. Over the last 30 years, he has held national, regional and global roles across the Pharmaceutical, medical device and diagnostics sectors.
|
| Mr Gavin Fox-Smith | Non-Executive Director | Dec 2024 |
Mr Smith has 38-year experience in Medical Technology in Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is an advocate for Gender Equality and Indigenous Engagement. Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Non-Executive Director for Omnigon, Bowel Cancer Australia and SAN Foundation.
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Mr Todd Perkinson | Chief Financial Officer |
-
|
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Catapult Investors Pty Ltd | 22,479,168 | 7.91% |
| HSBC Custody Nominees (Australia) Limited | 17,982,996 | 6.33% |
| Newfound Investments Pty Ltd | 13,905,407 | 4.89% |
| Loumea Investment Pty Ltd | 8,052,520 | 2.83% |
| J P Morgan Nominees Australia Pty Limited | 6,522,164 | 2.30% |
| Rojo Nero Capital Pty Ltd | 4,541,619 | 1.60% |
| Dc & Pc Holdings Pty Ltd | 4,465,567 | 1.57% |
| Ferndale Securities Pty Ltd | 4,300,000 | 1.51% |
| BNP Paribas Nominees Pty Ltd | 4,224,507 | 1.49% |
| Mr Martin Paul Breslin <The Mpb A/C> | 4,000,000 | 1.41% |
| Giokirptyltd | 3,661,470 | 1.29% |
| Mr Martin Paul Breslin | 3,175,000 | 1.12% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 3,000,000 | 1.06% |
| Mr Adrian Darby | 2,512,328 | 0.88% |
| Commonwealth Scientific And Industrial Research Organisation | 2,500,000 | 0.88% |
| Finclear Services Nominees Pty Limited | 2,325,463 | 0.82% |
| E&W Nominee Pty Ltd | 2,207,941 | 0.78% |
| Ms Natalie Louise Patterson | 2,200,000 | 0.77% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 2,150,000 | 0.76% |
| Mr Hsien Michael Soo | 2,134,442 | 0.75% |
